Calliditas Therapeutics Receives FDA Priority Review For Full Approval Of Nefecon For The Treatment Of IgA Nephropathy
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics has received FDA priority review for full approval of Nefecon, a treatment for IgA Nephropathy. This could potentially lead to a significant increase in the company's revenues if the drug is approved.
August 21, 2023 | 5:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas Therapeutics' drug Nefecon has received FDA priority review. This could potentially lead to a significant increase in the company's revenues if the drug is approved.
The FDA priority review of Nefecon indicates that the drug has potential to address an unmet medical need. If approved, this could lead to a significant increase in Calliditas Therapeutics' revenues, positively impacting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100